(0.33%) 5 116.77 points
(0.32%) 38 362 points
(0.38%) 15 989 points
(-1.00%) $83.01
(5.51%) $2.03
(0.32%) $2 354.70
(0.48%) $27.67
(4.13%) $960.20
(-0.26%) $0.932
(-0.44%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems...
Stats | |
---|---|
本日の出来高 | 738 646 |
平均出来高 | 713 522 |
時価総額 | 126.12M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.50 |
ATR14 | $0.0510 (1.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Morisset Valerie | Buy | 17 847 | Common Stock |
2024-04-05 | Morisset Valerie | Sell | 17 847 | Stock Option (Right to Buy) |
2024-03-18 | Pimblett Emily | Buy | 40 000 | Restricted Stock Units |
2023-09-20 | Morisset Valerie | Buy | 15 297 | Common Stock |
2023-09-20 | Morisset Valerie | Buy | 5 431 | Common Stock |
INSIDER POWER |
---|
39.96 |
Last 75 transactions |
Buy: 17 601 902 | Sell: 12 020 423 |
ボリューム 相関
Eliem Therapeutics, Inc. 相関 - 通貨/商品
Eliem Therapeutics, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.300 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.300 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.720 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.05 |
Financial Reports:
No articles found.
Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。